Clinical Trial Update: Saci Nivo Rela for TNBC [Phase 1, Phase 2]

View source ↗

Summary

A Yale University-sponsored Phase 1/2 clinical trial evaluating Sacituzumab govitecan in combination with nivolumab and relatlimab for metastatic triple-negativ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• OPDIVO (nivolumab)
• Relatlimab (relatlimab)
• TRODELVY (sacituzumab govitecan)

Snippet

Sponsor: Yale University | Conditions: Metastatic Triple-negative Breast Cancer | Phase 1, Phase 2 | Status: RECRUITING